Literature DB >> 11833844

Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium.

Yonggang Zhang1, Juxiang Li, Jun Cao, Jingjiong Chen, Jun Yang, Zhaokang Zhang, Junbao Du, Chaoshu Tang.   

Abstract

The cyclic peptide urotensin II (UII) has recently been cloned in mammals and reported to constrict rat pulmonary arteries potently. An enhanced maximal response was shown in rats exposed to chronic hypoxia. The aim of this study was to investigate changes in plasma and myocardial UII levels and its receptor sites in crude sarcolemma of ventricles from chronic hypoxic rats. We observed that rats exposed to chronic hypoxia for 4 weeks developed pulmonary hypertension and right ventricular hypertrophy. Compared with controls, the UII content in hypoxic rats was increased by 97.5% (45.24 +/- 7.1 vs. 22.9 +/- 3.24pg/mg protein, P < 0.01) in the right ventricle and 33.2% (24.89 +/- 0.99 vs. 18.68 +/- 2.04pg/mg protein, P < 0.01) in the left ventricle, respectively. However, there was no significant difference in plasma (27.44 +/- 3.11 vs. 27.82 +/- 5.57pg/ml, P > 0.05) and lung tissue levels (34.03 +/- 4.63 vs. 33.74 +/- 4.06 pg/ mg protein, P > 0.05) between the control and hypoxic groups. The time course of the binding of [125I]UII to crude ventricular sarcolemma was specific and time dependent. Scatchard plot analysis of the data demonstrated that the maximal number of specific binding sites (Bmax) in both the right and left ventricles was upregulated in the hypoxic group. Moreover, Bmax in the right ventricular specimens was upregulated to a greater extent than in the left ventricle (increased by 114% and 25% in the right and left ventricles, respectively, compared with control group, P < 0.01). In contrast, the UII binding affinity in right and left ventricular membranes from hypoxic rats was decreased (the dissociation constant Kd) increased by 20% and 33%, respectively compared with controls, P < 0.01). These results indicate that UII may act as an autocrine and/or paracrine hormone rather than as a circulating hormone, playing important roles in the development of ventricular hypertrophy induced by chronic hypoxia, and that the pathophysiological significance of UII in pulmonary and cardiovascular alteration induced by chronic hypoxia deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11833844     DOI: 10.1007/s380-002-8319-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  10 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

2.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

Review 3.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

Review 4.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 5.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

6.  The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1.

Authors:  Isabel Diebold; Andreas Petry; John Hess; Agnes Görlach
Journal:  Mol Biol Cell       Date:  2010-04-28       Impact factor: 4.138

7.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

8.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

9.  Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S Pathway.

Authors:  Hui Gong; Zhidan Chen; Xiaoyi Zhang; Yang Li; Jie Zhang; Ying Chen; Yingjiong Ding; Guoping Zhang; Chunjie Yang; Yichun Zhu; Yunzeng Zou
Journal:  Int J Mol Sci       Date:  2015-06-03       Impact factor: 5.923

10.  Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma.

Authors:  Alison Portnoy; Sanjay Kumar; David J Behm; Kelly M Mahar; Robert B Noble; John P Throup; Steven F Russ
Journal:  Front Pharmacol       Date:  2013-04-29       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.